JP2012522018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522018A5 JP2012522018A5 JP2012502314A JP2012502314A JP2012522018A5 JP 2012522018 A5 JP2012522018 A5 JP 2012522018A5 JP 2012502314 A JP2012502314 A JP 2012502314A JP 2012502314 A JP2012502314 A JP 2012502314A JP 2012522018 A5 JP2012522018 A5 JP 2012522018A5
- Authority
- JP
- Japan
- Prior art keywords
- inhalation
- dry powder
- powder suitable
- salt
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 claims 36
- 239000011780 sodium chloride Substances 0.000 claims 18
- 235000002639 sodium chloride Nutrition 0.000 claims 18
- 229910052751 metal Inorganic materials 0.000 claims 12
- 239000002184 metal Substances 0.000 claims 12
- 239000002245 particle Substances 0.000 claims 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 8
- -1 cation salt Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical group [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 6
- 239000007788 liquid Substances 0.000 claims 6
- 150000001768 cations Chemical class 0.000 claims 5
- 159000000000 sodium salts Chemical class 0.000 claims 4
- 229960004256 Calcium Citrate Drugs 0.000 claims 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H Calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims 3
- 239000001354 calcium citrate Substances 0.000 claims 3
- 159000000007 calcium salts Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 235000013337 tricalcium citrate Nutrition 0.000 claims 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 2
- 239000001110 calcium chloride Substances 0.000 claims 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims 2
- 229960002713 calcium chloride Drugs 0.000 claims 2
- 235000011148 calcium chloride Nutrition 0.000 claims 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 2
- 239000001509 sodium citrate Substances 0.000 claims 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 2
- 235000011152 sodium sulphate Nutrition 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 230000003068 static Effects 0.000 claims 2
- 239000011778 trisodium citrate Substances 0.000 claims 2
- 235000019263 trisodium citrate Nutrition 0.000 claims 2
- 229960004494 Calcium Gluconate Drugs 0.000 claims 1
- 229940095672 Calcium Sulfate Drugs 0.000 claims 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L Calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims 1
- NEEHYRZPVYRGPP-IYEMJOQQSA-L Calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 claims 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L Calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 206010038683 Respiratory disease Diseases 0.000 claims 1
- 229940005581 Sodium Lactate Drugs 0.000 claims 1
- NGSFWBMYFKHRBD-UHFFFAOYSA-M Sodium lactate Chemical compound [Na+].CC(O)C([O-])=O NGSFWBMYFKHRBD-UHFFFAOYSA-M 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 238000005349 anion exchange Methods 0.000 claims 1
- 159000000009 barium salts Chemical class 0.000 claims 1
- 239000001639 calcium acetate Substances 0.000 claims 1
- 229960005147 calcium acetate Drugs 0.000 claims 1
- 235000011092 calcium acetate Nutrition 0.000 claims 1
- 239000004227 calcium gluconate Substances 0.000 claims 1
- 235000013927 calcium gluconate Nutrition 0.000 claims 1
- 239000001527 calcium lactate Substances 0.000 claims 1
- 235000011086 calcium lactate Nutrition 0.000 claims 1
- 229960002401 calcium lactate Drugs 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 235000011132 calcium sulphate Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 229910003002 lithium salt Inorganic materials 0.000 claims 1
- 159000000002 lithium salts Chemical group 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 159000000001 potassium salts Chemical class 0.000 claims 1
- 230000000241 respiratory Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 239000001540 sodium lactate Substances 0.000 claims 1
- 235000011088 sodium lactate Nutrition 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Claims (27)
- 二価金属カチオン塩を含む吸入に適する乾燥粒子を含む吸入に適する乾燥粉末であって、前記二価金属カチオン塩は、前記乾燥粒子の約5重量%以上の量の二価金属カチオンを提供し、前記吸入に適する乾燥粒子は、レーザー回折(RODOS/HELOSシステム)で測定して、約10ミクロン以下または約5.0ミクロン以下の幾何学的体積中位径(VMGD)および約2未満または約1.5未満の分散性比率(1/4バール)を有する、吸入に適する乾燥粉末。
- 前記吸入に適する乾燥粉末は、前記粒子の約6重量%以上の量の一価カチオンを提供する一価塩をさらに含む、請求項1に記載の吸入に適する乾燥粉末。
- 前記吸入に適する乾燥粉末は、少なくとも45%の5.6ミクロン未満の細粒分(FPF)、少なくとも30%の3.4ミクロン未満の細粒分(FPF)または少なくとも45%の5.0ミクロン未満の細粒分(FPF)を有する、請求項1または2に記載の吸入に適する乾燥粉末。
- 前記吸入に適する乾燥粉末は、約5ミクロン以下の空気力学的質量中位径(MMAD)を有する、請求項1〜3のいずれか1項に記載の吸入に適する乾燥粉末。
- 前記二価金属カチオン塩は、水中で0.5g/L以上の溶解度を有する、請求項1〜4のいずれか1項に記載の吸入に適する乾燥粉末。
- 前記吸入に適する乾燥粒子は、リン酸カルシウムを含有しない、請求項1〜5のいずれか1項に記載の吸入に適する乾燥粉末。
- 二価金属カチオンの前記二価金属カチオン塩に対する分子量比は、約0.1より大きい、請求項1〜6のいずれか1項に記載の吸入に適する乾燥粉末。
- 前記吸入に適する乾燥粉末は、少なくとも1つの薬学的に許容される賦形剤をさらに含む、請求項1〜7のいずれか1項に記載の吸入に適する乾燥粉末。
- 前記少なくとも1つの賦形剤は、約50重量%以下の量で存在し、かつロイシン、マルトデキストリンまたはマンニトールを含む、請求項8に記載の吸入に適する乾燥粉末。
- 前記二価金属カチオン塩は、マグネシウム塩、バリウム塩およびカルシウム塩から成る群から選択される、請求項1〜9のいずれか1項に記載の吸入に適する乾燥粉末。
- 前記カルシウム塩は、硫酸カルシウム、クエン酸カルシウム、塩化カルシウム、酢酸カルシウム、グルコン酸カルシウム、乳酸カルシウムまたはそれらの任意の組み合わせである、請求項10に記載の吸入に適する乾燥粉末。
- 前記一価塩は、リチウム塩、カリウム塩またはナトリウム塩である、請求項1〜11のいずれか1項に記載の吸入に適する乾燥粉末。
- 前記ナトリウム塩は、塩化ナトリウム、クエン酸ナトリウム、乳酸ナトリウム、または硫酸ナトリウムである、請求項12に記載の吸入に適する乾燥粉末。
- 二価金属カチオン塩および一価塩を含む吸入に適する乾燥粒子を含む吸入に適する乾燥粉末であって、前記吸入に適する乾燥粒子は、非晶質二価金属カチオン相および結晶性一価塩相を含む、吸入に適する乾燥粉末。
- 前記非晶相のガラス転移温度は、少なくとも約120℃である、請求項14に記載の吸入に適する乾燥粉末。
- 前記非晶相は、賦形剤をさらに含む、請求項14または15に記載の吸入に適する乾燥粉末。
- 前記吸入に適する乾燥粉末は、0.5〜約5ミクロンのVMGDを有する、請求項14〜16のいずれか1項に記載の吸入に適する乾燥粉末。
- 前記二価金属カチオン塩は、カルシウム塩である、請求項17に記載の吸入に適する乾燥粉末。
- 前記一価塩は、ナトリウム塩である、請求項14〜18のいずれか1項に記載の吸入に適する乾燥粉末。
- 前記ナトリウム塩は、塩化ナトリウムである、請求項19に記載の吸入に適する乾燥粉末。
- 二価金属塩を含む吸入に適する乾燥粒子を含む吸入に適する乾燥粉末であって、前記二価金属塩は、前記乾燥粒子の約5重量%以上の量のカチオンを提供し、前記吸入に適する乾燥粉末は、1.5より大きいハウスナー比および2以下の1/4バールまたは0.5/4バールを有する、吸入に適する乾燥粉末。
- クエン酸カルシウムまたは硫酸カルシウムを含有する吸入に適する乾燥粒子を含む吸入に適する乾燥粉末であって、前記吸入に適する乾燥粒子は、
a)塩化カルシウムの水溶液を含む第1の液体供給原料と、硫酸ナトリウムまたはクエン酸ナトリウムの水溶液を含む第2の液体供給原料とを提供することと、
b)前記第1の液体供給原料および前記第2の液体供給原料を混合して、アニオン交換反応が起こる混合物を産生し、硫酸カルシウムおよび塩化ナトリウム、またはクエン酸カルシウムおよび塩化ナトリウムを含む飽和もしくは過飽和溶液を産生することと、
c)b)で産生された前記飽和もしくは過飽和溶液を噴霧乾燥して、吸入に適する乾燥粒子を産生することと、
を含む過程で産生される、吸入に適する乾燥粉末。 - b)において、前記第1の液体供給原料および前記第2の液体供給原料は、バッチ混合されるかまたは静的混合される、請求項22に記載の吸入に適する乾燥粉末。
- 静的混合後、得られた混合物は、5分以内に霧化される、請求項23に記載の吸入に適する乾燥粉末。
- 呼吸器疾患を治療するための、請求項1〜24のいずれか1項に記載の吸入に適する乾燥粉末を含有する医薬組成物。
- 呼吸器疾患の急性増悪を治療するための、請求項1〜24のいずれか1項に記載の吸入に適する乾燥粉末を含有する医薬組成物。
- 気道の感染性疾患を治療または予防するための、請求項1〜24のいずれか1項に記載の吸入に適する乾燥粉末を含有する医薬組成物。
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16376309P | 2009-03-26 | 2009-03-26 | |
US16376709P | 2009-03-26 | 2009-03-26 | |
US16377209P | 2009-03-26 | 2009-03-26 | |
US61/163,763 | 2009-03-26 | ||
US61/163,767 | 2009-03-26 | ||
US61/163,772 | 2009-03-26 | ||
US25576409P | 2009-10-28 | 2009-10-28 | |
US61/255,764 | 2009-10-28 | ||
US26774709P | 2009-12-08 | 2009-12-08 | |
US61/267,747 | 2009-12-08 | ||
US29809210P | 2010-01-25 | 2010-01-25 | |
US61/298,092 | 2010-01-25 | ||
US30581910P | 2010-02-18 | 2010-02-18 | |
US61/305,819 | 2010-02-18 | ||
PCT/US2010/028961 WO2010111680A2 (en) | 2009-03-26 | 2010-03-26 | Dry powder formulations and methods for treating pulmonary diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014256325A Division JP5964939B2 (ja) | 2009-03-26 | 2014-12-18 | 肺疾患を治療するための乾燥粉末製剤および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012522018A JP2012522018A (ja) | 2012-09-20 |
JP2012522018A5 true JP2012522018A5 (ja) | 2013-05-23 |
JP5671001B2 JP5671001B2 (ja) | 2015-02-18 |
Family
ID=42635067
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012502314A Active JP5671001B2 (ja) | 2009-03-26 | 2010-03-26 | 肺疾患を治療するための乾燥粉末製剤および方法 |
JP2014256325A Active JP5964939B2 (ja) | 2009-03-26 | 2014-12-18 | 肺疾患を治療するための乾燥粉末製剤および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014256325A Active JP5964939B2 (ja) | 2009-03-26 | 2014-12-18 | 肺疾患を治療するための乾燥粉末製剤および方法 |
Country Status (16)
Country | Link |
---|---|
US (3) | US20120064126A1 (ja) |
EP (2) | EP3184099A1 (ja) |
JP (2) | JP5671001B2 (ja) |
KR (1) | KR101639098B1 (ja) |
CN (2) | CN108434126B (ja) |
AU (1) | AU2010229668C1 (ja) |
BR (1) | BRPI1011721B1 (ja) |
CA (1) | CA2754691C (ja) |
DK (1) | DK2410981T4 (ja) |
ES (1) | ES2625260T5 (ja) |
HK (1) | HK1165709A1 (ja) |
IL (1) | IL215276A (ja) |
MX (1) | MX354829B (ja) |
PT (1) | PT2410981T (ja) |
RU (1) | RU2577698C2 (ja) |
WO (1) | WO2010111680A2 (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101639098B1 (ko) | 2009-03-26 | 2016-07-12 | 풀매트릭스 오퍼레이팅 컴퍼니, 인크 | 폐 질환 치료용 건조 분말 제형 및 방법 |
GB0918450D0 (en) * | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
CN105640925B (zh) | 2010-08-30 | 2019-08-16 | 普马特里克斯营业公司 | 干燥粉末配方及用于治疗肺部疾病的方法 |
EP2448571B1 (en) | 2010-08-30 | 2013-06-12 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
DK3470057T3 (da) | 2010-09-29 | 2021-11-22 | Pulmatrix Operating Co Inc | Kationiske tørpulvere omfattende magnesiumsalt |
MX354828B (es) | 2010-09-29 | 2018-03-22 | Pulmatrix Operating Co Inc | Polvos secos de cationes metálicos monovalentes para inhalación. |
WO2012058719A1 (en) * | 2010-11-02 | 2012-05-10 | The Universtity Of Sydney | Inhalable compositions |
MX346244B (es) | 2011-05-19 | 2017-03-13 | Savara Inc | Composiciones de vancomicina en polvo seco y metodos asociados. |
US9572774B2 (en) | 2011-05-19 | 2017-02-21 | Savara Inc. | Dry powder vancomycin compositions and associated methods |
US20140336159A1 (en) | 2011-10-07 | 2014-11-13 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
JP6231022B2 (ja) | 2012-02-28 | 2017-11-15 | アイシューティカ ホールディングス インク.Iceutica Holdings Inc. | 吸入可能な医薬組成物 |
AU2013225982B2 (en) | 2012-02-29 | 2017-11-30 | Pulmatrix, Inc. | Inhalable dry powders |
EP2879524B1 (en) | 2012-08-01 | 2016-09-07 | Purac Biochem bv | Lactate powder and method for the preparation thereof |
US8545878B1 (en) | 2012-11-09 | 2013-10-01 | Civitas Therapeutics, Inc. | Capsules containing high doses of levodopa for pulmonary use |
WO2014074797A1 (en) * | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
EP2754356A1 (en) | 2013-01-15 | 2014-07-16 | Purac Biochem N.V. | Improved nisin production process |
EP2769630B1 (en) | 2013-02-26 | 2016-04-27 | Purac Biochem N.V. | Improved nisin production process |
JP6473738B2 (ja) | 2013-04-01 | 2019-02-20 | パルマトリックス,インコーポレイテッド | チオトロピウム乾燥粉末 |
AU2013388034B2 (en) * | 2013-04-30 | 2019-08-15 | Vectura Inc. | Dry powder formulations and methods of use |
CA2923010C (en) * | 2013-09-03 | 2022-08-30 | Georgia Tech Research Corporation | Thermally stable vaccine formulations and microneedles |
ES2841933T3 (es) | 2014-10-31 | 2021-07-12 | Univ Monash | Formulación en polvo |
US10046007B2 (en) | 2015-06-24 | 2018-08-14 | Prescient Pharma, Llc | Compositions and methods for treatment of short telomere disorders |
US20170135969A1 (en) | 2015-11-12 | 2017-05-18 | Jds Therapeutics, Llc | Topical arginine-silicate-inositol for wound healing |
EP3463378A4 (en) | 2016-06-03 | 2020-01-08 | Otitopic Inc. | DRY POWDER FORMULAS FOR INHALATION |
MX2019002468A (es) | 2016-09-01 | 2019-09-18 | Jds Therapeutics Llc | Composiciones de biotinato de magnesio y metodos de uso. |
AU2019371825B2 (en) | 2018-11-02 | 2023-07-27 | Nutrition 21, Llc | Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers |
EP4076413A1 (en) | 2019-12-16 | 2022-10-26 | Nutrition 21, LLC | Methods of production of arginine-silicate complexes |
WO2023114375A2 (en) * | 2021-12-16 | 2023-06-22 | Alveolus Bio, Inc. | Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease |
WO2024046582A1 (en) * | 2022-09-02 | 2024-03-07 | Liita Care Aps | Pharmaceutical dry powder composition and methods for treating respiratory tract infections |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
US4233405A (en) | 1979-10-10 | 1980-11-11 | Rohm And Haas Company | Process for spray drying enzymes |
US4637815A (en) | 1985-08-06 | 1987-01-20 | Lemole Gerald M | Irrigational hemostatic solution |
US5511726A (en) | 1988-09-23 | 1996-04-30 | Battelle Memorial Institute | Nebulizer device |
IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
GB2265845B (en) | 1991-11-12 | 1996-05-01 | Medix Ltd | A nebuliser and nebuliser control system |
US5466680A (en) * | 1992-03-26 | 1995-11-14 | Cytologics, Inc. | Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
US6098620A (en) | 1993-01-29 | 2000-08-08 | Aradigm Corporation | Device for aerosolizing narcotics |
US5724957A (en) | 1993-01-29 | 1998-03-10 | Aradigm Corporation | Intrapulmonary delivery of narcotics |
NZ328476A (en) | 1993-06-24 | 1999-05-28 | Astra Ab | Use of a two component insulin preparation in an inhalation device |
AUPM411494A0 (en) | 1994-02-25 | 1994-03-24 | Central Sydney Area Health Service | Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum |
JP3414539B2 (ja) | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
US6586006B2 (en) | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
US5747002A (en) | 1995-04-05 | 1998-05-05 | Genentech, Inc. | Preparation of sodium chloride aerosol formulations |
US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
CA2218074C (en) | 1995-04-14 | 2002-10-08 | Mohammed Eljamal | Powdered pharmaceutical formulations having improved dispersibility |
ATE347391T1 (de) | 1995-04-14 | 2006-12-15 | Smithkline Beecham Corp | Dosierinhalator für fluticasonepropionat |
US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
US20050054682A1 (en) * | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
CZ292186B6 (cs) * | 1996-01-24 | 2003-08-13 | Altana Pharma Ag | Způsob výroby práškového prostředku s obsahem plicní povrchově aktivní látky, práškový prostředek a jeho použití |
GB9606677D0 (en) | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
JP2001517692A (ja) | 1997-09-29 | 2001-10-09 | インヘール セラピューティック システムズ, インコーポレイテッド | ネブライザにおける使用のための安定化調製物 |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
WO2000000215A1 (en) | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
DE69928279T2 (de) * | 1998-11-10 | 2006-08-17 | Altana Pharma Ag | Lungensurfactant zubereitungen enthaltendes behandlungset |
US6926911B1 (en) | 1998-12-22 | 2005-08-09 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
PT1150918E (pt) | 1999-02-03 | 2005-01-31 | Biosante Pharmaceuticals Inc | Metodo de fabrico de particulas terapeuticas de fosfato de calcio |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
GB9916316D0 (en) * | 1999-07-12 | 1999-09-15 | Quadrant Holdings Cambridge | Dry powder compositions |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
ATE285755T1 (de) * | 1999-08-25 | 2005-01-15 | Advanced Inhalation Res Inc | Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
HU229310B1 (en) | 1999-10-29 | 2013-10-28 | Nektar Therapeutics | Dry powder compositions having improved dispersivity |
SK284948B6 (sk) | 2000-04-06 | 2006-03-02 | Zentiva, A. S. | Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme |
WO2001076619A1 (en) * | 2000-04-12 | 2001-10-18 | Altana Pharma Ag | Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
EP1280520B2 (en) * | 2000-05-10 | 2018-03-21 | Novartis AG | Phospholipid-based powders for drug delivery |
EP1296651B2 (en) | 2000-06-27 | 2019-07-17 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
US7575761B2 (en) | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
EP2298285A3 (en) | 2000-11-30 | 2011-07-27 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
AU2002231244B2 (en) | 2000-12-27 | 2006-06-29 | Gilead Sciences, Inc. | Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections |
US20020141946A1 (en) | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US20050123509A1 (en) | 2001-10-19 | 2005-06-09 | Lehrman S. R. | Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
DK1455755T3 (da) * | 2001-11-20 | 2013-07-15 | Civitas Therapeutics Inc | Forbedrede partikelsammensætning til levering i lunge |
EP1466610A4 (en) | 2001-11-26 | 2007-03-21 | Daiichi Asubio Pharma Co Ltd | MEDICAL COMPOSITIONS FOR NASAL ABSORPTION |
AU2003215334A1 (en) | 2002-02-22 | 2003-09-09 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
US7008644B2 (en) | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
ES2487816T3 (es) | 2002-03-20 | 2014-08-25 | Civitas Therapeutics, Inc. | Administración pulmonar de levodopa |
GB0207906D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
LT1531794T (lt) † | 2002-06-28 | 2017-08-25 | Civitas Therapeutics, Inc. | Inhaliuojamas epinefrinas |
US20050288253A1 (en) * | 2002-09-09 | 2005-12-29 | Trigen Limited | Boronic acid salts |
KR20050056222A (ko) * | 2002-09-30 | 2005-06-14 | 아쿠스피어 인코포레이티드 | 흡입용 지속 방출형 다공성 미세입자 |
US7534781B2 (en) | 2003-03-21 | 2009-05-19 | Dsm Ip Assets B.V. | Crystalline amoxicillin trihydrate powder |
CN1194062C (zh) | 2003-04-04 | 2005-03-23 | 王泽斌 | 一种融雪融冰组合物及其制备方法和应用 |
EP1759695A1 (en) | 2003-05-01 | 2007-03-07 | Innogene Kalbiotech Pte. Ltd. | Lactate containing pharmaceutical composition and uses thereof |
JP2009514779A (ja) * | 2003-07-11 | 2009-04-09 | グラクソ グループ リミテッド | 医薬製剤 |
DE10339197A1 (de) * | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität |
GB0324897D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
GB0324918D0 (en) * | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
KR20050056622A (ko) | 2003-12-10 | 2005-06-16 | 주식회사 대우일렉트로닉스 | 플레쉬롬 다운로드 장치 |
WO2005067898A2 (en) * | 2004-01-07 | 2005-07-28 | Nektar Therapeutics | Improved sustained release compositions for pulmonary administration of insulin |
US20050207983A1 (en) | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
SE528121C2 (sv) | 2004-03-29 | 2006-09-05 | Mederio Ag | Preparering av torrpulver för på förhand uppmätt DPI |
CA2602596A1 (en) | 2004-03-30 | 2005-10-13 | Malcolm King | Compositions and methods for improved mucus function |
US20050281740A1 (en) | 2004-06-16 | 2005-12-22 | Glen Gong | Imaging damaged lung tissue |
MX2007000979A (es) | 2004-07-26 | 2007-07-11 | Cotherix Inc | Tratamiento de la hipertension pulmonar por iloprost inhalado con una formulacion microparticulada. |
US20060062739A1 (en) * | 2004-09-20 | 2006-03-23 | Thomas Hofmann | Inhalable lidocaine formulation for treatment of asthma and for reducing the need for corticosteroids in asthmatic patients |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
CN101247898B (zh) | 2005-05-05 | 2011-01-26 | 普马特里克斯公司 | 超音波气雾产生器 |
US7838532B2 (en) | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
BRPI0609924A2 (pt) * | 2005-05-18 | 2010-05-11 | Pulmatrix Inc | uso de uma formulação em aerossol contendo cerca de 0,5 a 20% (peso/peso) de um sal selecionado do grupo consistindo em um sal de magnésio, um sal de cálcio, um sal de alumìnio, um sal de silìcio, um sal de escándio, um sal de titánio, um sal de vanádio, um sal de cromo, um sal de cobalto, um sal de nìquel, um sal de cobre, um sal de manganês, um sal de zinco, um sal de estanho, e uma combinação dos mesmos, e composição farmacêutica |
GB0520794D0 (en) | 2005-10-12 | 2005-11-23 | Innovata Biomed Ltd | Inhaler |
GB0523576D0 (en) | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
GB0625322D0 (en) | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
US20090208582A1 (en) | 2008-02-13 | 2009-08-20 | Board Of Regents, The University Of Texas System | Templated Open Flocs of Anisotropic Particles for Enhanced Pulmonary Delivery |
EP2098219A1 (en) | 2008-03-05 | 2009-09-09 | PARI Pharma GmbH | Macrolide compositions having improved taste and stability |
US8834930B2 (en) | 2008-05-15 | 2014-09-16 | Novartis Ag | Pulmonary delivery of a fluoroquinolone |
GB0818476D0 (en) | 2008-10-09 | 2008-11-12 | Vectura Delivery Device Ltd | Inhaler |
JP2012522009A (ja) | 2009-03-26 | 2012-09-20 | パルマトリックス,インコーポレイテッド | 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法 |
CN102448438A (zh) | 2009-03-26 | 2012-05-09 | 普马特里克斯公司 | 抗流行性感冒调配物及方法 |
CN102448439A (zh) | 2009-03-26 | 2012-05-09 | 普马特里克斯公司 | 用于改变黏膜内衬的生物物理特性的柠檬酸钙及乳酸钙调配物 |
KR101639098B1 (ko) | 2009-03-26 | 2016-07-12 | 풀매트릭스 오퍼레이팅 컴퍼니, 인크 | 폐 질환 치료용 건조 분말 제형 및 방법 |
CA2754680A1 (en) | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Pharmaceutical formulations and methods for treating respiratory tract infections |
GB0918450D0 (en) | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
PT106094A (pt) | 2012-01-13 | 2013-07-15 | Hovione Farmaciencia S A | Administração por inalação de formulações com dose elevada |
-
2010
- 2010-03-26 KR KR1020117024843A patent/KR101639098B1/ko active IP Right Grant
- 2010-03-26 RU RU2011137960/15A patent/RU2577698C2/ru active
- 2010-03-26 EP EP17000124.2A patent/EP3184099A1/en active Pending
- 2010-03-26 US US13/259,635 patent/US20120064126A1/en not_active Abandoned
- 2010-03-26 AU AU2010229668A patent/AU2010229668C1/en active Active
- 2010-03-26 WO PCT/US2010/028961 patent/WO2010111680A2/en active Application Filing
- 2010-03-26 CN CN201810147094.3A patent/CN108434126B/zh active Active
- 2010-03-26 DK DK10713283.9T patent/DK2410981T4/da active
- 2010-03-26 ES ES10713283T patent/ES2625260T5/es active Active
- 2010-03-26 JP JP2012502314A patent/JP5671001B2/ja active Active
- 2010-03-26 MX MX2011009957A patent/MX354829B/es active IP Right Grant
- 2010-03-26 PT PT107132839T patent/PT2410981T/pt unknown
- 2010-03-26 EP EP10713283.9A patent/EP2410981B2/en active Active
- 2010-03-26 CN CN201080023554.3A patent/CN102497853B/zh not_active Expired - Fee Related
- 2010-03-26 CA CA2754691A patent/CA2754691C/en active Active
- 2010-03-26 BR BRPI1011721-0A patent/BRPI1011721B1/pt active IP Right Grant
-
2011
- 2011-09-21 IL IL215276A patent/IL215276A/en active IP Right Grant
-
2012
- 2012-06-29 HK HK12106373.0A patent/HK1165709A1/zh active IP Right Maintenance
-
2014
- 2014-12-18 JP JP2014256325A patent/JP5964939B2/ja active Active
-
2015
- 2015-03-25 US US14/667,857 patent/US9119778B2/en active Active
- 2015-07-21 US US14/804,940 patent/US9238005B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012522018A5 (ja) | ||
RU2011137960A (ru) | Сухие порошкообразные составы и способы лечения легочных заболеваний | |
AU2010229668B9 (en) | Dry powder formulations and methods for treating pulmonary diseases | |
JP2016065107A5 (ja) | ||
JP2013536845A5 (ja) | ||
RU2017145305A (ru) | Аморфный карбонат кальция, стабилизированный полифосфатами или бисфосфонатами | |
KR102082752B1 (ko) | 산과 금속 사이의 복합체의 분말 조성물 및 이의 제조방법 | |
JP2014524442A5 (ja) | ||
CN106511110B (zh) | 二氢燕麦生物碱d盐类化合物作为化妆品活性成分的应用及其合成方法 | |
TW201127407A (en) | Carnitine granulate and methods for its production | |
JP2004525108A5 (ja) | ||
CN105640925A (zh) | 干燥粉末配方及用于治疗肺部疾病的方法 | |
KR20120015295A (ko) | 점막 내층의 생물물리학적 성질의 변경을 위한 구연산 칼슘 및 젖산 칼슘 제형 | |
JP2017532374A5 (ja) | ||
JP4482925B2 (ja) | アミノ酸類粉末及びその製造方法 | |
MX2013013135A (es) | Proceso para producir un material inorganico particulado. | |
RU2015130602A (ru) | Соли и кристаллические формы | |
WO2013107236A1 (zh) | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 | |
JP2010533165A (ja) | S−アデノシルメチオニンの安定な塩およびその調製のための方法 | |
JP6562336B2 (ja) | 透析用a剤に使用される造粒物の製造方法 | |
CN1699337A (zh) | 氨溴索半胱氨酸类似物盐及其制备方法和用途 | |
JP2008007523A (ja) | 固形重曹透析用剤 | |
KR20190051850A (ko) | 무정형 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법 | |
ES2689517T3 (es) | Método para la fabricación de sal mineral y producto de sal mineral | |
EP3236949A1 (en) | Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof |